Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Feb 2;16(2):e0246173. doi: 10.1371/journal.pone.0246173

Clinical and whole genome characterization of SARS-CoV-2 in India

Radhakrishna Muttineni 1,#, Nagamani Kammili 2,#, Thrilok Chander Bingi 3,#, Raja Rao M 3,#, Kalyani Putty 4,#, Pankaj Singh Dholaniya 5,#, Ravi Kumar Puli 6, Sunitha Pakalapati 2, Saritha S 5, Shekar K 1, Mallikarjuna Reddy Doodipala 7, Amit A Upadhyay 8, Steven E Bosinger 9, Rama R Amara 8,*, Anand K Kondapi 5,¤,*
Editor: Binod Kumar10
PMCID: PMC7853523  PMID: 33529260

Abstract

We report clinical profile of hundred and nine patients with SARS CoV-2 infection, and whole genome sequences (WGS) of seven virus isolates from the first reported cases in India, with various international travel histories. Comorbidities such as diabetes, hypertension, and cardiovascular disease were frequently associated with severity of the disease. WBC and neutrophil counts showed an increase, while lymphocyte counts decreased in patients with severe infection suggesting a possible neutrophil mediated organ damage, while immune activity may be diminished with decrease in lymphocytes leading to disease severity. Increase in SGOT, SGPT and blood urea suggests the functional deficiencies of liver, heart, and kidney in patients who succumbed to the disease when compared to the group of recovered patients. The WGS analysis showed that these isolates were classified into two clades: I/A3i, and A2a (four according to GISAID: O, L, GR, and GH). Further, WGS phylogeny and travel history together indicate possible transmission from Middle East and Europe. Three S protein variants: Wuhan reference, D614G, and Y28H were identified predicted to possess different binding affinities to host ACE2.

Introduction

The coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first reported in December 2019 from Wuhan, China [1]. Coronaviruses are enveloped positive sense RNA viruses ranging from 60 nm to 140 nm in diameter with a genome size of approximately 26–32 kb [2]. They possess a crown like structure formed by glycoprotein Spike (S) protein on the virus facilitating its recognition to surface receptor, hence the name coronavirus [3]. In the 1960s, human coronaviruses (HCoVs) were first described in patients with common cold. Since then, seven HCoVs have been known to infect humans: 229E, OC43, SARS-CoV, NL63, HKU1, MERS-CoV (Middle East respiratory syndrome corona virus), and SARS-CoV-2 [46]. All the HCoVs are zoonotic with bats as key reservoirs of the virus [7, 8]. Over the last two decades, the world has experienced three different outbreaks caused by corona viruses with extremely high morbidity rates: SARS-CoV in 2002, MERS-CoV in 2012, and COVID-19 in 2019 [9, 10]. SARS-CoV-2 virus shows high pathogenicity of human transmission than MERS-CoV and SARS-CoV [11, 12].

With its complex disease morbidity and mortality, COVID-19 has raised global concern and is characterized as a pandemic event by the World Health Organization (WHO) on March 11, 2020. As reported by WHO, globally, as of 11 December, 2020, there have been 69,143,017 confirmed cases of COVID-19, including 1,576,516 deaths. Infections in India were reported from March 2020; as per the report by WHO there have been 9,796,769 confirmed cases of COVID-19 with 142,186 deaths in India as on 11th December 2020 [13].

Molecular features of the virus could be realized by undertesting genotypic and phenotypic properties of the viruses. Whole genome sequence (WGS) data is an excellent resource in understanding the evolution of the virus, assist in tracing pathways promoting infection, etc; understanding of which can assist in the development of diagnostics, therapeutic and preventive strategies. The SARS CoV-2 genomic resource GISAID database (https://www.gisaid.org/) contained a compilation of 70,614 SARS-CoV-2 complete genomes contributed by researchers from across the world by 23rd July 2020. Among these, 305 complete genome sequences of Indian SARS-CoV-2 isolates were archived on GISAID. Phylogenetic analysis revealed clustering of Indian isolates with existing global sequences of SARS-CoV-2 in two separate clusters indicating two different introductions of the virus genotype into the country [14]. Furthermore, the virus exhibited 96.09% nucleotide identity with Bat CoV RaTG13 sequence, though phenotypically they exhibit distinct features [14]. For a comprehensive understanding of SARS-CoV-2 evolution, including different evolutionary strategies adapted by the virus, continuous monitoring of WGS of the virus strains from different parts of the world is crucial. The primary objective of the current study is to present clinical profile of hundred and nine SARS-CoV-2 patients admitted to a COVID-19 referral Gandhi hospital, Hyderabad, Telangana State, India of which fifty-seven patients recovered and fifty-two patients succumbed to the illness. Secondary objectives are to: a) perform comprehensive WGS analysis of seven strains of SARS-CoV-2 from among the first reported (during February-March, 2020) SARS-CoV-2 cases in Hyderabad, India with international travel history from Europe, USA, Indonesia, and United Arab Emirates. These patients were screened for COVID-19 symptoms at Rajiv Gandhi International airport, Hyderabad, India, quarantined, and were tested positive for COVID-19 by RT-PCR. These patients were admitted in the COVID referral hospital in Hyderabad and enrolled in the study. b) identify changes in the structure of spike protein among the isolates, and c) quantify differential expression of host ACE2 in the seven different cases.

Materials and methods

Ethical approval

This study was approved by Institutional ethics committee, and was carried out as per the Institutional ethics committee approval No. IEC/GMC/2020/02/40 dated 04/04/2020 of Gandhi Medical College and Hospital. In the context of emerging infectious disease conditions, the requirement for written informed consent was waived.

Clinical specimen collection and detection of SARS-CoV-2 nucleic acid

Clinical specimens for SARS-CoV-2 diagnostic testing were obtained in accordance with WHO guidelines [13]. Nasopharyngeal and oropharyngeal swab specimens were collected with synthetic fiber swabs; each swab was inserted into a separate sterile tube containing 2 to 3 ml of viral transport medium (QIAGEN). RNA extraction was preformed using QIAamp Viral RNA Mini Kit (QIAGEN, Cat#52906) as per the manufacturer’s instructions. The extracted RNA was immediately used for testing the presence of SARS-CoV-2 nucleic acid using the real time RT-PCR protocol [14] recommended by National institute of virology, Pune, India, using Super Script™ III Platinum® One-Step Quantitative Kit (Invitrogen, Cat. No.11732088) [15].

Clinical records

The medical records of the SARS-CoV-2 positive patients were analysed by the research team, Department of General Medicine, COVID-19 referral Gandhi Hospital and Medical College, Hyderabad, India. Physicians and researchers reviewed the clinical, laboratory, radiological characteristics, and treatment measures of the patients.

Whole genome sequencing

The WGS was carried out at Med Genome Labs Ltd., Bangalore, India. NEB Ultra II directional RNA-Seq Library Prep kit (NEB, Cat# E7760L) was used to prepare libraries for total RNA sequencing. Libraries were pooled and diluted to final optimal loading concentrations for cluster amplification on Illumina flow cell followed by sequencing on Illumina HiSeq X instrument to generate 150bp paired end reads. The quality of the reads was evaluated using Fast QC v0.11.9 [16] and cut adapt v2.9 [17] was used to trim adapters and remove contaminants. The reads were aligned to the human reference genome hg19 using STAR v2.4 [18]. The reads that do not align to the human reference were aligned to the Wuhan reference genome downloaded from NCBI (Ref Seq NC_045512.2) using BWA v.0.7.12 aligner [19]. The reads mapping to the genes were counted using bed tools v2.26.0 [20]. The aligned reads were sorted, and then variant calling was performed using GATK variant caller v 4.1.0.0 [21]. The variants identified were then annotated to the genes. The variant class, amino acid changes and other relevant annotations were added to the variants. The variants were then compared with the genomes available in NCBI and GISAID database.

Phylogeny reconstruction

Phylogenetic analysis of the WGS data of samples was performed by multiple sequence alignment of the sequences with the genomes available in NCBI and GISAID database. The phylogenetic tree in newick file format was downloaded from Indian Coronavirus Genome Datasets maintained by CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB; http://clingen.igib.res.in/genepi/phylovis/) for Indian SARS-CoV-2 sequences and visualized using FigTree v1.4.4. Further, BLAST was performed for each sequence of the current study on the GISAID database against all the SARS-CoV-2 genome sequences. Top 30 sequence hits for each isolate were downloaded and merged into a single file. This resulted in total of 142 sequences which also included the seven sequences of the current study. The sequence alignment was performed using MUSCLE program available in MEGA v10.1.7, and the phylogenetic tree was reconstructed using Neighbor-joining method and Kimura 2 parameter as nucleotide substitution model with 1000 bootstrap values. For phylogenetic analysis of the S protein, protein sequences of SARS-CoV-2 S protein of all Indian isolates were downloaded from GISAID database. The multiple sequence alignment was performed using MUSCLE algorithm in MEGA v10.1.7. The phylogenetic tree was reconstructed using Neighbor-joining method with 1000 bootstrap validation and p-distance substitution model.

Structural analysis of spike protein

Homology modelling based on the spike sequence was carried out using Swiss Model [22]. Obtained model was further optimized using fragment guided molecular dynamics simulation [23]. Optimized model was visualized in Pymol. Trimeric spike protein optimized above was docked using protein-protein docking using ClusPro Srver; highest neigbours were taken as most probable conformation. Docked conformation was visualized in Pymol [2426]. Binding constant & energy, and dissociation constant values were computed at Web server PRODIGY [27].

Statistical analysis

In the current study, categorical variables were described as frequency rates and percentages; continuous variables were described as mean, median, and interquartile range. Means for continuous variables were compared using independent two sample t- test statistics (for two-tail) when the data were normally distributed. On the other hand, categorical type variables were investigated using a non-parametric Mann-Whitney-U-test. For determining the proportions for categorical variables, a non-parametric Chi-square test was used, then complete data was cross tabulated (rows v/s columns) and analyzed. The Fisher exact test was used when the data were limited. In each case, a two-sided α of less than 0·05 was considered as statistically significant. The statistical analyses were done using SPSS ver. 20 software.

Results and discussion

Clinical, radiological, functional, and immunological profile of COVID-19 patients

The current study enrolled patients (N = 109) diagnosed for SARS-CoV-2 during February 2020 to May 2020, admitted to a tertiary referral hospital in Hyderabad, India. Patients exhibiting hypoxia, shortness of breath, altered sensorium, haemoptysis, acute kidney injury (AKI), chronic kidney disease (CKD), aphasia, chest pain, dysphagia, oral ulcers, hypoxia, metabolic encephalopathy, renal failure, tracheostomy care, and sudden syncope were admitted to intensive care unit (ICU). Majority of the patients had frequently reported fever (37%) and cough (39%). Patients with comorbidities such as diabetes (33%), hypertension (31%), CKD (7%), and cardio vascular disease (CVD) (9%) became severely ill, even when intervened through respiratory support along with oxygen, and medical support with antibacterials, antivirals, hydroxy chloroquine (HCQ), and steroids. Conditions such as cancer (1%), septic shock (11%), acute respiratory distress syndrome (ARDS) (40%), CKD (5%), non-ICU sudden collapse (1%), were seen in patients that could not be recovered and succumbed to the disease (Table 1). For clinical comparison in the current study, the patients were grouped in to recovered (R) (N = 57; male (n): 37, female (n): 20, aged 3 years-72 years) and succumbed (S) (N = 52; male (n): 41, female (n):11, aged 2 months-85 years). Median age of recovered patients was found to be 32 years (26y-35y), and death patients to be 61 years (35y-85y). Between R and S groups there was a significant difference (P<0.05) in favour of S group in the onset of certain symptoms (fever, cough, breathing difficulty, and crepts) and comorbidities (diabetes, hypertension, systolic blood pressure, diastolic blood pressure, and asthma) (Table 1). Significant difference (P<0.05) between these two groups (in favour of S group) was also observed in ECG, viral Ct values, majority of the pathological lung radiological findings (Table 1, Fig 1). Interestingly, significant difference in favor of S group was noticed with supportive therapy. Supportive therapy was provided with antibiotics (cefotaxime, azithromycin), antivirals (oseltamivir and lopinavir/ritonavir), HCQ, and steroids. This suggests that the treatment started in severely ill patients had no effect in the recovery of the patients. This also suggests that supportive therapy although statistically found significant, has no effective role in disease outcome.

Table 1. Comparison of clinical findings among Recovered (R) and Succumbed group (S).

Parameter Number Recovered number (R) Succumbed number (S) P value
Number of patients 109(100%) 57(52%) 52 (48%) -
Median age in years (IQR) 46(41–50) 32(26–35) 61(35–85) <0.0001*
Sex (Male, Female median age in years) 51, 37 46, 27 61, 47 <0.0001*
Male 78(71%) 37(64%) 41(78%) 0.02*
Female 31(28%) 20(35%) 11(21%) 0.02*
Signs & Symptoms
Fever 40(37%) 8(14%) 32(62%) 0.03*
Cough 42(39%) 10(17%) 32(62%) <0.0001*
Sore throat 8(7%) 4(7%) 4(7%) 0.36
Headache 6(6%) 3(5%) 3(5%) 0.28
Cold/Loss of Smell/Sneezing 1(1%) 0 1(1%) 0.9
Breathing difficulty 46(42%) 2(3%) 44(84%) <0.001*
Respiratory Rate>24 breaths per min 83(76%) 51 (89%) 32(61) <0.001*
SP O2 (%) 85(78) 57(100) 28(54) <0.001*
Retractions 3(2%) 0 3(5%) 0.31
Crepts 23(21%) 0 23(44%) 0.02*
Diarrhoea 5(4%) 0 5(9%) 0.13
Comorbidities
Diabetes 37(33%) 5(8%) 32(61%) <0.001*
<5 12(11%) 5(8%) 7(13%) <0.001*
5–25 25(22%) 0 25(48%) <0.001*
Hypertension 34(31%) 3(5%) 31(60%) <0.001*
<5 12(11%) 3(5%) 9(17%) <0.001*
5–25 22(20%) 0 22(42%) <0.001*
Systolic Blood Pressure Median (IQR) 120(110–130) 120 (110–128) 131(110–150) <0.0001*
Diastolic Blood Pressure median (IQR) 85(80–92) 80 (80–90) 79(60–90) <0.0001*
CVD (Cardio Vascular Disease) (yrs) 10(9%) 1(1%) 9(17%) 0.04*
<5 8(7%) 1(1%) 7(13%) 0.04*
>5 2(1%) 0 2(3%) 0.04*
CKD (Chronic Kidney Disease) 8(7%) 0 8(15%) 0.99
Hypothyroidism 5(5%) 0 5(10%) 0.99
Asthma 5(4%) 1(1%) 4(7%) 0.01*
ECG
Normal sinus rhythm 55(50%) 54(94%) 1(1%) <0.001*
Sinus tachy 19(17%) 1(1%) 18(35%) <0.001*
Median Heart Rate/PR bpm (IQR) 80(75–110) 86(78–95) 102(80–123) <0.001*
RNA CT Values (median, IQR)
E 18(15–25) 20(18–22) 20(17–23) <0.04*
RdRP 26(20–35) 28(23–32) 24(21–26) <0.01*
ORF 24(20–31) 26(24–28) 23(21–25) <0.01*
Date of illness to Recovery/Death
Date of illness to recovery (median days)/Death Days (IQR) 15(10–20) 16(8–20) 9(6–12) 0.04*
Length of hospital stay in days 13(11–21) 16(7–20) 9(4–12) 0.04*
Radiological Findings
Normal 44(40%) 39(68%) 5(9%) <0.001*
Infiltrations 19(17%) 1(1%) 18(35%) <0.001*
Haziness 7(6%) 3(5%) 4(7%) <0.001*
GGO 7(6%) 1(1%) 6(11%) <0.001*
Consolidation 4(3%) 2(3%) 2(3%) <0.001*
Treatment
Antibiotic 53(49%) 11(19%) 42(80%) <0.001*
Antiviral 51(47%) 9(16%) 42(80%) <0.001*
Hydroxy Chloroquine 18(16%) 1(1%) 17(28%) <0.05*
Steroid 4(3%) 0(0) 4(7%) <0.001*
Cause of Death
ARDS (Acute respiratory distress syndrome) 21(19%) 0 21(40%) 0.49
CKD (Chronic kidney disease) 3(3%) 0 3(5%) 0.50
Septic Shock 6(5%) 0 6(11%) 0.56
Non-ICU Sudden Death 1(1%) 0 1(1%) -
Cancer 1(1%) 0 1(1%) -
Meningoencephalitis 1(1%) 0 1(1%) -

Numbers in the brackets indicate percentage of patients enrolled in the current study that are exhibiting the respective parameters; unless mentioned otherwise.

*Indicates significant difference.

Fig 1. Chest computed tomographic, and X-ray images.

Fig 1

a) Chest CT images of sample ID RK100 showing chest consolidation in central areas of RT upper lobe, RT middle lobe and bilateral basal areas b) Chest X ray of sample ID KN443 showing sub pleural ground glass opacities in bilateral mid and lower zones Lt>Rt haziness c) Chest X ray of sample ID RR1191showing bilateral lower zone and left retro cardiac consolidation, Lt>Rt haziness d) multifocal bilateral ground glass opacities and patchy consolidation in a patient suffering with COVID-19.

Cause of death was significant (P<0.05) due to ARDS, CKD, and septic shock. Other non-significant causes of death include meningoencephalitis, cancer and non-ICU related sudden death (Table 1). It was shown previously that 90% of the deaths were due to ARDS followed by CKD (18%), and shock (12%) [28]. Previous studies reported that comorbidities, particularly the CVDs and chronic pulmonary diseases, were important to predict the in-hospital mortality in critically ill patients [29]. Our study reports that majority of patients in the S group had underlying diseases, especially hypertension, lung disease, and heart disease, more often with more than one comorbidity in individual patient. Sepsis was also a common complication found in this study, which might be directly caused by SARS-CoV-2 infection; further research is needed to investigate the pathogenesis of sepsis in COVID-19 illness.

In this study, radiological findings were obtained in only 40% of cases due to various logistic reasons. 35% of S group had infiltrates in two or more lobes, and almost 68% had normal radiological findings in R group (Fig 1). Overall, the findings commonly included patchy ground glass opacity (GGO) (11%) followed by confluent haziness (7%) in S group; in contrast consolidation was equal in both groups. Overall, our study highlights the radiological findings were consistent with the severity of infection varying from infiltrations through GGO to consolidations.

When immune response of R and S groups was compared, the results show a higher WBC and neutrophil count in the S group (Table 2). Neutrophilia is a hallmark of any acute infection. It was also suggested before that aberrant activation of neutrophils contribute to the exacerbated host response in patients with severe COVID-19, predicting poor outcome [30]. Importantly neutrophil infiltration was also observed in pulmonary capillaries of COVID-19 patients leading to acute capillaritis with fibrin deposition, extravasation of neutrophils into the alveolar space, and neutrophilic mucositis [31]. In addition to this, the role of neutrophilia as a source of excess neutrophil extracellular traps (NETs) was also shown before [32]. NETs are web-like structures of DNA and proteins expelled from the neutrophils that capture and kill the pathogens [33]. In addition to being useful, excessive NET formation can trigger a cascade of inflammatory reactions that results in permanent organ damage to the pulmonary, cardiovascular, and renal systems, the most commonly affected organ systems in severe COVID-19 [6, 3438].

Table 2. Functional and immunological parameters of COVID-19 patients with variable severities.

Functional Parameter (SI Units) Normal Range All Patients(N = 109) Median (IQR) Recovered (N = 57) Succumbed (N = 52) P Values
Total Serum Bilirubin, umol/L 1.71–20.52 5.23 (4.99–15.91) 5.385 (4.96–16.58) 19.41 (18.82–40.5) <0.05*
Serum Creatinine, umol/L 61.88–114.9 64.5 (58.95–119.12) 63.64 (40.66–86.62) 92.33 (90.56–150.36) <0.001*
BU mmol/L 1.16–3.33 3.39 (1.21–5.57) 2.11 (2.03–5.41) 6.00 (5.68–15.34) <0.001*
SGOT/AST, Units/Lit 8.01–45 43.01 (43.55–95.13) 13.43 (13.01–38.72) 42.64 (40.00–90.5) <0.001*
SGPT/ALT, Units/Lit 7.01–56 19.05 (18.10–41.3) 8.16 (5.56–27.08) 21.92 (15.87–71.79) <0.001*
AP, U/Lit 44–147 117.5 (77.2–131.61) 46.56 (42.56–133.7) 48.38 (43.68–139.84) 0.7
Na, mmol/Lit 136–145 138.00 (132.91–144.84) 139.54 (137.57–144.51) 140.6 (129.43–146.4) <0.05*
K,mmol/Lit 3.5–5.0 4.23 (3.45–5.01) 4.16 (3.53–4.79) 2.15 (3.36–5.24) 0.42
CL,mmol/Lit 98–107 102.33 (96.81–107.85) 102.36 (98.83–106.89) 102.23 (95.1–109.54) <0.001*
Immunology Normal Range All Patients(N = 109) Median (IQR) Recovered Succumbed P Values
WBC X 10^9/L 4.5–10 4.8(4.24–13.96) 4.55 (4.35–12.47) 6.37 (6.12–14.86) <0.05*
Neutrophils, X10^9/L 2.5–7.5 3.38 (2.56–10.95) 2.40 (2.22–7.36) 5.52 (4.43–13.63) <0.05*
LymphocytesX10^9/L 1–4.8 1.25 (0.7–4.15) 1.66 (1.56–5.06) 0.64 (0.39–2.17) 0.52
Monocytes, X10^9/L 0.2–0.6 0.4 (0.32–0.96) 0.38 (0.37–0.97) 0.59 (0.45–1.68) 0.16
Eosinophiils, X10^9/L 0.03–0.35 0.115 (0.07–0.53) 0.12 (0.08–0.56) 0.23 (0.21–0.97) 0.88
Platelets, X10^9/L 150–450 250 (167.88–268.12) 273 (250–450) 263 (250–500) 0.14

Another interesting finding was that the lymphocyte count was low in S group compared to R group (Table 2); such a decrease in lymphocyte count was reported previously in pneumonia patients [39, 40]. This suggests that the increased lymphocytes in the R group may be contributing for the recovery of the patients, while lymphocytes may be damaged in the condition of severe infection condition, thus reducing recovery of S group. Lymphocytes play an important role in the maintenance of immune system function. After virus infection, alteration in total lymphocyte numbers varies with different viral pathogenic mechanisms [41]. Several mechanisms were shown before for virus induced lymphopenia including immune injuries from inflammatory mediators, virus attachment, exudation of circulating lymphocytes into inflammatory lung tissues [39]. Recent studies indicated a clear association of decrease in peripheral lymphocytes with the clinical characteristics of COVID-19 patients [39]. This indicates an impairment of the immune system during the course of SARS-CoV-2 infection. These alterations were also found in patients with pneumonia caused by MERS- CoV and SARS-CoV [42]. Marginal differences were seen in monocyte, eosinophil and platelet counts between R and S groups (Table 2).

When functional parameters were compared, large deviation of serum glutamic-oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT) and blood urea was seen when mean values were taken in consideration (Table 2). There was a significant increase in SGPT, SGOT and blood urea in S group compared to R group (Table 2). There was no significant change seen in alkaline phosphatase (AP), which indicates that liver may not be severely affected. Higher SGOT and SGPT levels could be due to effect of infection to both heart and liver [43]. Since blood urea was also significantly increased in S group, the observed increase may also be associated with comorbid diabetes in these patients (Table 2). In summary, neutrophil and lymphocyte count, the levels of SGOT and SGPT in COVID-19 patients may provide an indication on severity of the infection in Indian population infected with SARS CoV-2, while the comorbid conditions such as diabetes, hypertension and CVD would further enhance the complexity of the disease condition. Death was reported in the patients on an average of 9 (6–12) days of hospitalization, while recovery was noticed with in 16 (8–20) days of hospitalization (Table 1). A previous study reported number of days from hospital admission to death is 6.35+/-4.51 days [44].

Hospitalization was shorter in death patients, which is most likely due to rapid progression of disease in such severe cases. As per the recent health bulletin released by the Govt. of Telangana, India, maximum number of deaths were reported in the age group of 51–60 (N = 52), followed by 61–70 (N = 48), 41–50 (N = 42), and 71–80 (N = 26) [45, 46]. Studies from China have reported similar findings that majority of the affected patients were middle aged and elderly people with median age of deceased patients being 69 years [28, 47]. It is evident that respiratory distress is the major cause of mortality. It is possible that ageing diminishes the lung function, regeneration, and remodelling thereby enhancing its susceptibility to the disease [48].

Next generation sequencing

From the first reported cases in India that had international travel histories from USA, UK, Italy, Indonesia, United Arab Emirates during 20-02-2020 to 25-03-2020, n = 7 samples were sent to whole genome sequencing (n = 6 from R group and n = 1 from S group). > 4.9 Gb data was obtained by 151bp pair end sequencing. Of the total, more than 80% of bases have base quality > = Q30. The raw reads were pre-processed for adapter and contamination removal. Of the total raw reads, ~50–64% of the total reads were left after pre-processing. Out of total pre-processed reads, ~50–77% align to the host transcriptome/genome (human-hg19) using STAR aligner. The unaligned reads from host analysis were converted to fastq and then aligned to the SARS-CoV-2 reference genome (Genbank Ref seq NC_045512.2). A total of >200,000 reads mapped to the viral genome for all the samples, and of these 97% of the reads were properly paired. Coverage analysis of the genome showed 100% coverage for all the samples with an average read depth of >225X. Of the total bases of interest ~100% of the genome have more than 100X depth. The full-genome viral sequences were deposited in the dataset of GISAID (EPI_ISL_431101, EPI_ISL_431102, EPI_ISL_431103, EPI_ISL_431117, EPI_ISL_438139, EPI_ISL_437626, EPI_ISL_438138) and NCBI GenBank (MT415320, MT415321, MT415322, MT415323, MT477885, MT457402, MT457403).

Genetic variation in the sequences

Mutations among the seven SARS-CoV-2 strains, were identified both at the genome level and corresponding amino acid level throughout the whole genome, with reference to the prototype SARS-CoV-2 Wuhan strain genome (NCBI Ref Seq NC_045512.2) (Table 3). Two synonymous (15324C>T in ORF1ab; 24130C>T in S) and two nonsynonymous mutations (21644T>C{Y28H} in the S gene; 29303C>T{P344S} in the N gene) were observed in the sample (OUMRK100/2020) collected from patient with travel history to Dubai. One synonymous (3037C>T in ORF1ab) and two nonsynonymous mutations (14408C>T{P4714L} in ORF1ab; 23403A>G{D614G} in the S gene) were observed in the sample (GMCKN318/2020) collected from patient with travel history to Italy. One synonymous (23929C>T in the S gene) and four nonsynonymous mutations (6312C>A{T2016K}, 11083G>T{L3606F}, 13730C>T{A4489V} in ORF1ab; 28311C>T{P13L} in the N gene) were observed in the sample (GMCKN443/2020) collected from patient with travel history to Indonesia. One synonymous (3037C>T in ORF1ab) and four nonsynonymous mutations (14408C>T{P4714L} in ORF1ab; 23403A>G{D614G} in the S gene; 28881G>A{R203L}, 28883G>C{G204R} in the N gene) were observed in the sample (GMCTC469/2020) collected from patient with travel history to UK. One synonymous (23929C>T in the S gene) and four nonsynonymous mutations (6312 C>A{T2016N}, 11083G>T{L3606F}, 13730C>T{A4489V} in ORF1ab; 28311C>T{P13L} in the N gene) were observed in the sample (OUMRK1090/2020) collected from patient with travel history to UAE. Two synonymous (3037C>T, 18877C>T in ORF1ab) and three nonsynonymous mutations (14408C>T{P4714L} in ORF1ab; 23403 A>G{D614G} in the S gene; 25563G>T{Q57H} in the N gene) were observed in the sample (GMCKP1125/2020) collected from patient with travel history to USA. One synonymous (23929C>T in the S gene) and four nonsynonymous mutations (6312 C>T{T2016K}, 11083G>T{L3606F}, 13730C>T{A4489V} in ORF1ab; 28311C>T{P13L} in the N gene) were observed in the sample (GMCRR1191/2020) collected from patient with cluster infection and no travel history, and who succumbed to the disease.

Table 3. Nucleotide polymorphisms and amino acid changes throughout the seven genomes.

ORF1 ab Spike ORF3a Nucleocapsid
N AA N AA N AA N AA N AA N AA N AA N AA N AA N AA N AA N AA N AA N AA
3037 925 6312 2,016 11,083 3,606 13,730 4,489 14,408 4,715 15,324 5,020 18,877 6205 21644 28 23403 614 23929 789 24130 856 25563 57 28311 13 29303 344
Wuhan Hu-1 C F C T G L C A C P C N C L T Y A D C Y C N G Q C P C P
OUMRK100/2020 C F C T G L C A C P T N C L C H A D C Y T N G Q C P T S
GMCKN318/2020 T F C T G L C A T L C N C L T Y G G C Y C N G Q C P C P
GMCKN443/2020 C F C K T F T G C P C N C L T Y A D T Y C N G Q T L C P
GMCTC469/2020 T F C T G L C A T L C N C L T Y G G C Y C N G Q C P C P
OUMRK1090/2020 C F A N T F T V C P C N C L T Y A D T Y C N G Q T L C P
GMCKP1125/2020 T F C T G L C A T L C N T L T Y G G C Y C N T H C P C P
GMC-RR1191/2020 C F A K T F T V C P C N C L T Y A D T Y C N G Q T L C P

Orf1ab is a poly-protein, which, after translation, is cleaved into 15 nonstructural proteins (NSP). Total 4 nonsynonymous mutations were observed at 4 different positions among different samples. Mutation at position 6312 C>T{T2016K} is on NSP3 in sample GMCKN443/2020, GMCRR1191/2020, and OUMRK1090/2020. NSP3 has 10 different conserved domains including the nucleic acid binding domain (cl24732: NAR superfamily). The mutation 6312 C>T{T2016K} falls on relative position of 1198 on NSP3 protein sequence. This position is related to the nucleic acid binding domain. The mutation 11083G>T{L3606F} was observed in NSP6 in sample GMCKN443/2020, GMCRR1191/2020, and OUMRK1090/2020. NSP6 is a 1945 amino acid long peptide containing putative transmembrane domain. In pp1ab it ranges from amino acid 3570 to 3895. Two mutations were observed in NSP11, in which the first mutation 13730:C>T{A4489V} was present in samples GMCKN443/2020 GMCRR1191/2020 and OUMRK1090/2020; and the second 14408:C>A{P4714L} was observed in samples GMCKN318/2020, GMCTC469/2020, and GMCKP1125/2020. NSP11 is RNA-dependent RNA polymerase (RdRp) having one conserved domain SARS-CoV-like RdRp (cd21591) (Fig 2).

Fig 2. Graphical representation of polyprotein synthesized by orf1ab (taken form NCBI sequence viewer).

Fig 2

The four different mutations observed in 6 different samples were mapped based on the position. Out of four, two mutations were observed in NSP3 and NSP6 each. The remaining two mutations were observed in RNA-dependent RNA polymerase (NSP11).

N gene codes for nucleocapsid phosphoprotein (N Protein). Four different variants in N protein were reported among six out of seven different samples. The mutation 28311C>T{P13L}, was found in three samples GMCKN443/2020, OUMRK1090/2020, GMCRR1191/2020, while one mutation in each was observed in other three samples. The N protein of SARS-CoV-2 shares 90% sequence similarity with the N protein of SARS-CoV [49]. The N-protein is a RNA binding protein and has three intrinsically disordered regions (IDRs) from residues 1–44, 182–247 and 366–422 in case of SARS-CoV, which may modulate the RNA-binding activity [50, 51]. The two mutations out of four in N-protein reported from our analysis (28311C>T{P13L} and 28883G>C{G204R}) are present in IDRs suggesting there may be variation for RNA binding activity among the N-protein of different variants of SARS-CoV-2.

Several mutations were observed among the seven isolates with both synonymous and nonsynonymous mutations with pyrimidine exchanges (C to T or T to C) suggesting the possibility of occurrence of transcription-induced mutations [52]. This could be due to high replication rates of the virus. Nonsynonymous mutations showed higher frequency than synonymous mutations in the ORF regions of the viral genomes suggesting that the selection of mutation may be biased towards viral phenotype changes which may be contributing to the observed variability in the severity of infection reported in different epidemiological studies [53].

Phylogenetic analyses

The genomes sequenced in the current study were found to be in two clades, when analysed with the other available Indian SARS-CoV-2 sequences. Four of the seven sequences belong to clade-I/A3i; of which three sequences (OUMRK1090/2020, GMCRR1191/2020, and GMCKN443/2020) are clustered together, and one sequence (OUMRK100/2020) clustered separately in the same clade. The other three sequences (GMCTC469/2020, GMCKP1125/2020, and GMCKN318/2020) belong to the clade A2a in three different clusters (Fig 3). The sequences were further analyzed with other SARS-CoV-2 sequences worldwide (Fig 4). It can be seen that the virus sequence from patient with travel history to Dubai (OUMRK100/2020) clustered with sequences from UAE, Japan, and the original Wuhan-Hu-1 strain. Virus sequences from patients with travel history to Indonesia (GMCKN443/2020), UAE (OUMRK1090/2020), and no travel history (GMCRR1191/2020) clustered together along with two other Indian isolates, and a Singapore isolate. Sample GMCKP1125/2020 isolated from patient who travelled to India from USA via UAE can be seen closely clustered with one USA and three Saudi Arabian isolates. Virus sequence from patient with travel history to UK (GMCTC469/2020); and Italy (GMCKN318/2020) were found to be clustered with other England, Italian; and USA, Russian strains, respectively. The global comparison according to GISAID database revealed that three sequences from the current study: GMC-RK1090, GMC-RK1191, and GMC-KN443 are in the cluster labeled as clade O according the GISAID database. Other four sequences belonged to four different clades: L (GMC-RK100), G (GMC-KN318), GR (GMC-TC469) and GH (GMC-KP1125) (Fig 5).

Fig 3. Phylogenetic tree of Indian SARS-CoV-2 sequences according to the dataset available at CSIR Institute of Genomics and Integrative Biology.

Fig 3

The sequences form the current study are labeled in black font. Sequences OUMRK1090/2020, GMCRR1191/2020, GMCKN443/2020, and OUMRK100/2020 are in clade I/A3i. Sequences GMCTC469/2020, GMCKP1125/2020, and GMCKN318/202 are clustered in clade A2a.

Fig 4. Phylogenetic tree of Indian SARS-CoV-2 isolates with sequences worldwide.

Fig 4

Indian SARS-CoV-2 sequences of the current study are shown in red.

Fig 5. The clustering of the isolates in the current study in the phylogenetic tree of all SARS-CoV-2 sequences globally according to the GISAID database.

Fig 5

These findings, suggest that there might be two distinct points of transmission: one is involving Middle East, and other Europe, this could be a transition point during travel for an airway transmission of the virus. A previous study suggested that divergence from a single point of Clade I/A3i suggests a single point of introduction into the country, and that the spread from this could be from a single outbreak [54]. The first sequence from this cluster in India was GMC-KN443 which was from a patient who travelled to India from Indonesia. However, the authors suggested that the strain is similar to those strains from Singapore and Philippines [54]. Furthermore, another study reported that isolate RK100 clustered with the ancestral first isolates from India that were originally reported from Kerala [55].

Analysis of spike protein

Protein sequences for spike protein of SARS-CoV-2 of all Indian isolates were downloaded from GISAID database. Total 53 sequences were obtained in which 4 sequences (EPI_ISL_431101, EPI_ISL_431102, EPI_ISL_431103, and EPI_ISL_431117) were from Hyderabad isolates. The multiple sequence alignment was performed using MUSCLE algorithm in MEGA v10.1.7. The phylogenetic tree was constructed using Neighbor-joining method with 1000 bootstrap validation and p-distance substitution model. The results show four different genotypic variants (Fig 6). Among these, three amino acid variations were observed including reference Wuhan isolate. RK100 showed Y28H mutation, while sample nos KN318, TC469, and KP1125 showed D614G mutation, and samples KN443, RK1090 and RR1191 spike protein are similar to Wuhan reference. Thus, among seven samples there are three phenotypic variants of spike protein.

Fig 6. The phylogenetic tree of SPIKE protein from all the seven Indian Isolates.

Fig 6

Total 53 different types of proteins were identified in GISAID database to date. Among seven Hyderabad isolated total 4 different types of Spike proteins are observed (Red).

Structure prediction analysis of spike protein shows that overall structure of isolated viruses may not be significantly affected, while loop regions connected to beta sheets are varied among the spike proteins of four variants. When predicted affinity of spike protein with ACE2 was analysed through docking, the results showed that spike protein of RK100 may be interacted between position 470–490 and 200–220, while KN318, TC469 and KP1125 spike protein may be interacting with ACE2 between position 250–270 and 630–650 (Fig 7). In case of KN443, RK1090 and RR1191, spike protein interacts with ACE2 between position 70–80, 120–160, 170–250 and 470–485. When energy of interaction and binding constant was compared with Wuhan reference, the results showed that the binding affinity RK100 and KN318 decreased by 5615 and 6000-fold, respectively. Thus, suggesting that the virus affinity to ACE2 receptor could be varied among the three variants of the isolates in circulation (Table 4).

Fig 7. Spike protein ACE2 docking.

Fig 7

Comparison of predicted docking origination of ACE2 interaction with (A) RK100 (Y28H) interacts with ACE2 through its residues 623 to 639 along with 293 Leu and 28 His; (B, D) KN443, RK1090 and RR1191 interacting ACE2 through its residues 152 to 184; (C) KN318, TC469 and KP1125 (D614G) interreacts ACE2 through its residues 623 to 639. 614G is located in loops. AA being referred is indicated in pink dots. Panel (ii) of 7A, 7B, 7C, and 7D indicates zoomed in image of AA side chains involved in interaction that was depicted in panel (i), respectively.

Table 4. Energy and dissociation constants of interaction of Spike protein with host ACE2.

Docked structure with ACE2 Binding Affinity (Kcal/mol) Dissociation constant (M) ACE2 Expression (FPKM) in Sample
RK100 -50.6 7.8E-38 0.5576
KN318 -49.9 2.6E-37 4.1271
TC469 -49.9 2.6E-37 0.1397
KP1125 -49.9 2.6E-37 1.5134
KN443 -55.8 1.3E-41 0.3940
RK1090 -55.8 1.3E-41 0.4303
RR1191 -55.8 1.3E-41 0.4722

We observed 3 distinct variants Y28H (RK100), D614G (KN318, TC469, KP1125), and similar to Wuhan reference NC_045512.2 (KN443, RK1090 and RR1191). These mutations were distinctly different with varied affinities as assessed by theoretical analysis, wherein the affinity of Wuhan was higher followed by Y28H and D614G (Table 4). When RNA reads for ACE2 were quantified, it shows higher variability among the patients, but the ACE2 expression (0.13 to 1.51) (Table 4) could not be correlated with the predicted affinity of the S protein to ACE2 of isolates and also Ct values. A larger WGS sample size, which is a limitation of the current study, can provide better insights in this area. It was interesting to note comparatively low Ct values (high viral loads) in the Spike G614 variants when compared to D614 variants (E gene: 19±1 vs 22±2; RdRp: 26±0 vs 27±5; ORF: 25±1 vs 28±3).

Conclusion

Clinical profile of COVID-19 in India majorly shows fever and cough; comorbid diabetes, hypertension, and CVD were associated with increased severity of infection. Increased neutrophil count, decreased lymphocyte count, increased levels of SGOT, SGPT and blood urea were also associated with increased severity of infection. The observations in X-ray and CT scan confirms the severity of infection. A limitation of the current study is the inability to retrieve all the data regarding radiological findings. This hindered us to compare the findings extensively in both groups. It is hoped that findings from this study will guide clinicians to identify patients with different prognosis at an early stage based on the clinical characteristics presented by patients, and help in providing appropriate and effective management for the patients. Sequence analysis of seven patients of SARS CoV-2 in India showed they are under two clades I/A3i, A2a; and O, L, GR, and GH clades as per the latest GISAID classification. Analysis of the S protein showed that they belong to three variants with distinct predicted ACE2 interaction. ACE2 expression levels were variable among the patients.

Supporting information

S1 File

(XLS)

Acknowledgments

We thank Dr. Rajith Kumar, IAS, Principal Secretary, Telangana State council Science and Technology, Government of Telangana, Dr.G.Prakash Rao Principal, Gandhi Medical College and Hospital, Dr.A.Vinaya Sekhar, HOD, Department of General Medicine, GMC, Hyderabad, Prof. S. Satayanarayana, Former Vice Chancellor, Osmania University, Hyderabad for their support, and Medgenome, Bangalore for their technical support in WGS. We are indebted to all the patients and staff from Department of Microbiology and General Medicine, Gandhi Medical College and Hospital who assisted in this study. We sincerely appreciate the researchers worldwide who sequenced and shared the complete genome data of SARS-CoV-2 and other coronaviruses from GISAID (https://www.gisaid.org/). Dr. Kondapi participated in the analysis during his sabbatical period.

Data Availability

All relevant data are within the paper and its Supporting Information file.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382: 727–733. 10.1056/NEJMoa2001017 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Weiss SR, Navas-Martin S. Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus. Microbiol Mol Biol Rev. 2005;69: 635–664. 10.1128/MMBR.69.4.635-664.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Richman DD. Clinical Virology, 4th Edition. Available: https://www.wiley.com/en-us/9781555819422
  • 4.Kin N, Miszczak F, Lin W, Ar Gouilh M, Vabret A, Consortium E. Genomic analysis of 15 human coronaviruses OC43 (HCoV-OC43s) circulating in France from 2001 to 2013 reveals a high intra-specific diversity with new recombinant genotypes. Viruses. 2015;7: 2358–2377. 10.3390/v7052358 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. Journal of Medical Virology. John Wiley and Sons Inc.; 2020. pp. 401–402. 10.1002/jmv.25678 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395: 507–513. 10.1016/S0140-6736(20)30211-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and Sources of Endemic Human Coronaviruses. Advances in Virus Research. Academic Press Inc.; 2018. pp. 163–188. 10.1016/bs.aivir.2018.01.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Brook CE, Dobson AP. Bats as “special” reservoirs for emerging zoonotic pathogens. Trends in Microbiology. Elsevier Ltd; 2015. pp. 172–180. 10.1016/j.tim.2014.12.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Peiris JSM, Lai ST, Poon LLM, Guan Y, Yam LYC, Lim W, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet. 2003;361: 1319–1325. 10.1016/s0140-6736(03)13077-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Raj VS, Osterhaus ADME, Fouchier RAM, Haagmans BL. MERS: Emergence of a novel human coronavirus. Current Opinion in Virology. Elsevier B.V.; 2014. pp. 58–62. 10.1016/j.coviro.2014.01.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395: 514–523. 10.1016/S0140-6736(20)30154-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Lillie PJ, Samson A, Li A, Adams K, Capstick R, Barlow GD, et al. Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission. Journal of Infection. W.B. Saunders Ltd; 2020. pp. 578–606. 10.1016/j.jinf.2020.02.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.India: WHO Coronavirus Disease (COVID-19) Dashboard | WHO Coronavirus Disease (COVID-19) Dashboard. [cited 11 Dec 2020]. Available: https://covid19.who.int/region/searo/country/in
  • 14.Yadav P, Potdar V, Choudhary M, Nyayanit D, Agrawal M, Jadhav S, et al. Full-genome sequences of the first two SARS-CoV-2 viruses from India. Indian J Med Res. 2020;0: 0 10.4103/ijmr.IJMR_663_20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G, Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event. Infect Genet Evol. 2020;79 10.1016/j.meegid.2020.104212 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Leggett RM, Ramirez-Gonzalez RH, Clavijo BJ, Waite D, Davey RP. Sequencing quality assessment tools to enable data-driven informatics for high throughput genomics. Front Genet. 2013;4: 288 10.3389/fgene.2013.00288 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet.journal. 2011;17: 10 10.14806/ej.17.1.200 [DOI] [Google Scholar]
  • 18.Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. Sequence analysis STAR: ultrafast universal RNA-seq aligner. 2013;29: 15–21. 10.1093/bioinformatics/bts635 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. 2010;26: 589–595. 10.1093/bioinformatics/btp698 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Quinlan AR, Hall IM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinforma Appl NOTE. 2010;26: 841–842. 10.1093/bioinformatics/btq033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Brouard JS, Schenkel F, Marete A, Bissonnette N. The GATK joint genotyping workflow is appropriate for calling variants in RNA-seq experiments. J Anim Sci Biotechnol. 2019;10: 44 10.1186/s40104-019-0359-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46 10.1093/nar/gky427 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zhang J, Liang Y, Zhang Y. Atomic-level protein structure refinement using fragment-guided molecular dynamics conformation sampling. Structure. 2011;19: 1784–1795. 10.1016/j.str.2011.09.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Vajda S, Yueh C, Beglov D, Bohnuud T, Mottarella SE, Xia B, et al. New additions to the ClusPro server motivated by CAPRI. Proteins Struct Funct Bioinforma. 2017;85: 435–444. 10.1002/prot.25219 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Kozakov D, Beglov D, Bohnuud T, Mottarella SE, Xia B, Hall DR, et al. How good is automated protein docking? Proteins Struct Funct Bioinforma. 2013;81: 2159–2166. 10.1002/prot.24403 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, et al. The ClusPro web server for protein-protein docking. Nat Protoc. 2017;12: 255–278. 10.1038/nprot.2016.169 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Xue LC, Ao J, Rodrigues P, Kastritis PL, Bonvin AM, Vangone A. Structural bioinformatics PRODIGY: a web server for predicting the binding affinity of protein-protein complexes. 2016. [cited 18 Jul 2020]. 10.1093/bioinformatics/btw514 [DOI] [PubMed] [Google Scholar]
  • 28.Deng Y, Liu W, Liu K, Fang Y-Y, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J (Engl). 2020;133: 1261–1267. 10.1097/CM9.0000000000000824 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Ladha KS, Zhao K, Quraishi SA, Kurth T, Eikermann M, Kaafarani HMA, et al. The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients. BMJ Open. 2015;5: 8990 10.1136/bmjopen-2015-008990 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA—J Am Med Assoc. 2020;323: 1061–1069. 10.1001/jama.2020.1585 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. [A pathological report of three COVID-19 cases by minimally invasive autopsies]. Zhonghua bing li xue za zhi = Chinese J Pathol. 2020;49: E009 10.3760/cma.j.cn112151-20200312-00193 [DOI] [PubMed] [Google Scholar]
  • 32.Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM, et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. Journal of Experimental Medicine. Rockefeller University Press; 2020. 10.1084/jem.20200652 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. Neutrophil Extracellular Traps Kill Bacteria. Science (80-). 2004;303: 1532–1535. 10.1126/science.1092385 [DOI] [PubMed] [Google Scholar]
  • 34.Schönrich G, Raftery MJ. Neutrophil extracellular traps go viral. Frontiers in Immunology. Frontiers Media S.A.; 2016. p. 366 10.3389/fimmu.2016.00366 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Jorch SK, Kubes P. An emerging role for neutrophil extracellular traps in noninfectious disease. Nature Medicine. Nature Publishing Group; 2017. pp. 279–287. 10.1038/nm.4294 [DOI] [PubMed] [Google Scholar]
  • 36.Kessenbrock K, Krumbholz M, Schönermarck U, Back W, Gross WL, Werb Z, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med. 2009;15: 623–625. 10.1038/nm.1959 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Papayannopoulos V, Staab D, Zychlinsky A. Neutrophil Elastase Enhances Sputum Solubilization in Cystic Fibrosis Patients Receiving DNase Therapy. Hartl D, editor. PLoS One. 2011;6: e28526 10.1371/journal.pone.0028526 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Bonow RO, Fonarow GC, O’Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) with Myocardial Injury and Mortality. JAMA Cardiology. American Medical Association; 2020. pp. 751–753. 10.1001/jamacardio.2020.1105 [DOI] [PubMed] [Google Scholar]
  • 39.Wang F, Nie J, Wang H, Zhao Q, Xiong Y, Deng L, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. 2020. 10.1093/infdis/jiaa150 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. 2020. 10.1093/cid/ciaa248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Li T, Qiu Z, Zhang L, Han Y, He W, Liu Z, et al. Significant Changes of Peripheral T Lymphocyte Subsets in Patients with Severe Acute Respiratory Syndrome. J Infect Dis. 2004;189: 648–651. 10.1086/381535 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.He Z, Zhao C, Dong Q, Zhuang H, Song S, Peng G, et al. Effects of severe acute respiratory syndrome (SARS) coronavirus infection on peripheral blood lymphocytes and their subsets. Int J Infect Dis. 2005;9: 323–330. 10.1016/j.ijid.2004.07.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: Retrospective study. BMJ. 2020;368 10.1136/bmj.m1091 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. Am J Respir Crit Care Med. 2020;201: 1372–1379. 10.1164/rccm.202003-0543OC [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.(No Title). [cited 7 Dec 2020]. Available: https://covid19.telangana.gov.in/wp-content/uploads/2020/06/Media-Bulletin-17-06-2020.pdf [Google Scholar]
  • 46.(No Title). [cited 7 Dec 2020]. Available: https://covid19.telangana.gov.in/wp-content/uploads/2020/06/Media-Bulletin-19-06-2020.pdf [Google Scholar]
  • 47.Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. www.thelancet.com. 2020;395: 497. 10.1016/S0140-6736(20)30183-5 [DOI] [PMC free article] [PubMed]
  • 48.Cho SJ, Stout-Delgado HW. Aging and Lung Disease. Annu Rev Physiol. 2020;82: 433–459. 10.1146/annurev-physiol-021119-034610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host Microbe. 2020;27: 671–680.e2. 10.1016/j.chom.2020.03.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Chang C-K, Hsu Y-L, Chang Y-H, Chao F-A, Wu M-C, Huang Y-S, et al. Multiple Nucleic Acid Binding Sites and Intrinsic Disorder of Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Protein: Implications for Ribonucleocapsid Protein Packaging. J Virol. 2009;83: 2255–2264. 10.1128/JVI.02001-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Chang CK, Hou MH, Chang CF, Hsiao CD, Huang TH. The SARS coronavirus nucleocapsid protein—Forms and functions. Antiviral Research. Elsevier; 2014. pp. 39–50. 10.1016/j.antiviral.2013.12.009 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Beletskii A, Bhagwat AS. Transcription-induced mutations: Increase in C to T mutations in the nontranscribed strand during transcription in Escherichia coli. Proc Natl Acad Sci U S A. 1996;93: 13919–13924. 10.1073/pnas.93.24.13919 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. 2020. 10.1016/j.cell.2020.05.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Banu S, Jolly B, Mukherjee P, Singh P, Khan S, Zaveri L, et al. A distinct phylogenetic cluster of Indian SARS-CoV-2 isolates. bioRxiv. 2020;19: 202005.31.126136. 10.1101/2020.05.31.126136 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Bhattacharjee B, Pandit B. Phylogenetic clustering of the Indian SARS-CoV-2 genomes reveals the presence of distinct clades of viral haplotypes among states 2 *Correspondance. bioRxiv. 2020; 2020.05.28.122143. 10.1101/2020.05.28.122143 [DOI] [Google Scholar]

Decision Letter 0

Binod Kumar

Transfer Alert

This paper was transferred from another journal. As a result, its full editorial history (including decision letters, peer reviews and author responses) may not be present.

5 Nov 2020

PONE-D-20-25334

Clinical and Whole Genome Characterization of SARS-CoV-2 in India

PLOS ONE

Dear Dr. Kondapi,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. One of the reviewers has pointed major changes and must be addressed in the manuscript.

Please submit your revised manuscript by Dec 20 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Binod Kumar, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating in the text of your manuscript:

"The study was carried out as per the Institutional Ethics Committee approval No. IEC/GMC/2020/02/40 dated 04/04/2020 of Gandhi Medical College and Hospital. In the

context of emerging infectious disease conditions, the requirement for written informed consent was waived."

Please also add this information to your ethics statement in the online submission form and specifically state that your study was approved by the ethics committee.

3. Thank you for stating the following financial disclosure:

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

  1. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

  2. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

  3. If any authors received a salary from any of your funders, please state which authors and which funders.

  4. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

* Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear Associate Editor,

The manuscript 'Clinical and Whole Genome Characterization of SARS-CoV-2 in India’ by Kondappi et al analyze the clinical and biochemical profile and whole genome sequences of patients with SARS-CoV-2 in a tertiary hospital in India and thereby providing some guidelines that might aide in the treatment of those patients at an early stage. However, there are some concerns in this manuscript, which the authors have failed to address.

Major comment:

1. In the introduction, the authors nicely summarize about the various strains of human coronaviruses and its complications, however they have missed to cite many key literatures in the text.

a. The key reference of SARS-CoV-2 (Zhu et al, NEJM 2020) according to their statement in the first sentence is missing.

b. There are no references in the second paragraph of the introduction, which includes the statements about WHO and India. Without a proper reference, the sentence on the mitigation efforts by the Indian government looks like an overstatement, since the number of cases appear to have risen just before this manuscript was submitted.

c. Since one of the important finding in this study is focused on the comparison of different strains and mutations and the samples have been obtained from patients with international history, there should be a sentence on how this particular information was collected and their authenticity.

2. One of the aims in this study is to present the clinical difference amongst the SARS-CoV-2 patients. For this reason, the authors need to present this section more clearly and understandable. However, there is so much confusion and disparity in this section in both the text and the table.

a. It is understandable the authors are making a comparison of those patients who recovered and succumbed and draw comparison to other studies. However, this part is confusing as their classification in the text is based on the patient’s age groups and also their outcome, whereas the table is focused only on the latter.

b. In table 1, those items written within the brackets are confusing, therefore it will be better if those items in the bracket are listed for each and every item listed in the rows of the table.

c. There is a disparity in the number and the frequency for the cause of death in table 1.

d. Rather than writing ‘significant difference’, the authors should explicitly write as increased or decrease of that particular component when you compare R to S group.

3. In table 1, the authors indicate there was a significant difference between R and S group in regards to the supportive therapy. Can the authors comment and discuss on which drugs were used and what impact they had?

4. The role of increased neutrophils in SARS-CoV-2 should be discussed properly rather than just providing a statement from the reference. Similarly, the role of decreased lymphocytes in context of SARS-CoV-2 (if not in other Coronavirus infections) should also be discussed.

5. The authors do not mention anything about the ORF1ab, ORF3a, Spike, nucleocapsid or about ACE2 in the methods section and they also do not discuss about their importance or relevance to SARS-CoV-2 in this manuscript. The authors indicate the whole genome sequencing was performed only in patients with international travel history, but not in others, is there a reason as to why there is a bias in this, as they anyway compare their sequences to those available from worldwide to determine the points of transmission.

6. In the conclusion, the authors mention the patients exhibit higher immunological response compared to previous published reports. It is not clear as to what they mean by higher immunological response.

7. In the conclusion, the authors mention the radiological findings confirms the severity of infection. This is not clear, as they do not interpret the radiological findings in figure 1 as to how it is related to SARS-CoV-2. In addition to that, the authors need to indicate the number of patients for whom the radiological diagnosis were performed and their criteria, if any.

Minor comments:

1. The authors need to pay attention to the errors related to English grammar in the results section and address that.

2. The authors should also provide references in the methods section, wherever necessary, and this includes their description on sample collection by WHO guidelines and using the manufacturer/others protocol.

3. In the results section, the opening paragraph is not required, since the exact same information has been provided under the clinical and biochemical profile.

4. The authors need to pay attention to the abbreviation when a particular word is written for the first time in the text or table.

5. It would be better if the authors indicate which statistical tests were used for comparing the difference between R and S groups in table 1 along with the results.

6. Which disease does reference 27 indicate?

7. Ratios are usually indicated as 1:2 and not as a number with +, clarity should be provided on the neutrophil and lymphocyte ratio.

8. There is no reference for indicating SGOT and SGPT levels are associated with heart and liver infection.

9. There is no reference for the health bulletin provided by Telangana government.

10. In Figure 2, is the Clade – I/A3a or I/A3i, they are different in the text and figure.

11. Is there any scale to distinguish between the two different panels in figure 6 A-D?

Reviewer #2: This study is pertinent, considering the raging current pandemic. Authors of this report provided a correlation of increased risk of severe illness with underlying conditions and immunological responses in the Indian patients. This report will help in better management of patients in the clinical settings.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Godhev Manakkat Vijay

Reviewer #2: Yes: Vikram Srivastava

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 2;16(2):e0246173. doi: 10.1371/journal.pone.0246173.r002

Author response to Decision Letter 0


12 Dec 2020

Response to reviewer’s comments/suggestions for manuscript entitled “Clinical and whole genome characterization of SARS-CoV-2 in India”

We thank you for considering the manuscript for publication in PLoS One. We thank the reviewers for providing constructive comments and helping with improvement of the manuscript quality. We have gone through each point carefully and the necessary answers are given below point by point.

Response to the Editorial comments:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Ans: We have followed the style template provided in PLoS One website in the revised version.

2. Thank you for stating in the text of your manuscript:

"The study was carried out as per the Institutional Ethics Committee approval No. IEC/GMC/2020/02/40 dated 04/04/2020 of Gandhi Medical College and Hospital. In the context of emerging infectious disease conditions, the requirement for written informed consent was waived." Please also add this information to your ethics statement in the online submission form and specifically state that your study was approved by the ethics committee.

Ans: As per the journal’s suggestion, the necessary details are now included in the online submission form.

3. Thank you for stating the following financial disclosure:

"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

a. Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution.

Ans: The authors received no specific funding for this work.

b. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Ans: The authors received no specific funding for this work. Hence not applicable to this manuscript.

c. If any authors received a salary from any of your funders, please state which authors and which funders.

Ans: Not applicable for the current study.

d. If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Ans: As per the journal’s suggestion, the necessary details are now included in line 516 of the revised manuscript.

Response to the major comments of the reviewers:

1. In the introduction, the authors nicely summarize about the various strains of human coronaviruses and its complications, however they have missed to cite many key literatures in the text.

a. The key reference of SARS-CoV-2 (Zhu et al, NEJM 2020) according to their statement in the first sentence is missing.

Ans: As per the reviewer’s suggestion, Zhu et al, NEJM 2020 is now cited as reference 1 in line 77 of the revised manuscript.

b. There are no references in the second paragraph of the introduction, which includes the statements about WHO and India. Without a proper reference, the sentence on the mitigation efforts by the Indian government looks like an overstatement, since the number of cases appear to have risen just before this manuscript was submitted.

Ans: As per the reviewer’s suggestion, WHO statistics are updated as reference 13 in lines 94 of the revised manuscript. The following statement is deleted from the revised manuscript: “Prompt intervention by Government of India and the health authorities made the spread of infection under manageable limit”.

c. Since one of the important finding in this study is focused on the comparison of different strains and mutations and the samples have been obtained from patients with international history, there should be a sentence on how this particular information was collected and their authenticity.

Ans: As per the reviewer’s suggestion, the necessary details are now included in lines 113-119 of the revised manuscript as follows: “perform comprehensive WGS analysis of seven strains of SARS-CoV-2 from among the first reported (during February-March, 2020) SARS-CoV-2 cases in Hyderabad, India with international travel history from Europe, USA, Indonesia, and United Arab Emirates. These patients were screened for COVID-19 symptoms at Rajiv Gandhi International airport, Hyderabad, India, quarantined, and were tested positive for COVID-19 by RT-PCR. These patients were admitted in the COVID referral hospital in Hyderabad and enrolled in the study.”

2. One of the aims in this study is to present the clinical difference amongst the SARS-CoV-2 patients. For this reason, the authors need to present this section more clearly and understandable. However, there is so much confusion and disparity in this section in both the text and the table.

a. It is understandable the authors are making a comparison of those patients who recovered and succumbed and draw comparison to other studies. However, this part is confusing as their classification in the text is based on the patient’s age groups and also their outcome, whereas the table is focused only on the latter.

Ans: As per the reviewer’s suggestion, to simplify and for ease of understanding, patients are now only grouped as “recovered” and “succumbed”. Since comparison of clinical and biochemical parameters was not done as per the age, the following statement is deleted from the revised manuscript: “The patients were divided into four different age groups, child (3-12 years old; N=6), adolescent (13-18 years old; N=6), adult (19-59 years old; N=62), and senior (> 60 years old; N=35)”. Also, this part of the results section is edited to be presented clearly. Please refer to lines 200-312 of the revised manuscript.

b. In table 1, those items written within the brackets are confusing, therefore it will be better if those items in the bracket are listed for each and every item listed in the rows of the table.

Ans: The numbers in the brackets indicate percentage of patients enrolled in the current study that are exhibiting the respective parameters.

c. There is a disparity in the number and the frequency for the cause of death in table 1.

Ans: As per the reviewer’s suggestion, this was noted and now corrected.

d. Rather than writing ‘significant difference’, the authors should explicitly write as increased or decrease of that particular component when you compare R to S group.

Ans: As per the reviewer’s suggestion, the necessary details are now included in the revised manuscript.

3. In table 1, the authors indicate there was a significant difference between R and S group in regards to the supportive therapy. Can the authors comment and discuss on which drugs were used and what impact they had?

Ans: Supportive therapy was provided with antibiotics (cefotaxime, Azithromycin), antivirals (oseltamivir and lopinavir/ritonavir), hydroxy chloroquine, and steroids. Interestingly, significant difference in favor of S group was noticed with supportive therapy. This suggests that the treatment started in severely ill patients had no effect in the recovery of the patients. This also suggests that supportive therapy although statistically found significant, has no effective role in disease outcome. The same is mentioned in lines 223-228 of the revised manuscript.

4. The role of increased neutrophils in SARS-CoV-2 should be discussed properly rather than just providing a statement from the reference. Similarly, the role of decreased lymphocytes in context of SARS-CoV-2 (if not in other Coronavirus infections) should also be discussed.

Ans: Neutrophilia is a hallmark of any acute infection. It was also suggested before that aberrant activation of neutrophils contribute to the exacerbated host response in patients with severe COVID-19, predicting poor outcome. Importantly neutrophil infiltration was also observed in pulmonary capillaries of COVID-19 patients leading to acute capillaritis with fibrin deposition, extravasation of neutrophils into the alveolar space, and neutrophilic mucositis. In addition to this, the role of neutrophilia as a source of excess neutrophil extracellular traps (NETs) was also discussed. NETs are web-like structures of DNA and proteins expelled from the neutrophils that capture and kill the pathogens. In addition to being useful, excessive NET formation can trigger a cascade of inflammatory reactions that results in permanent organ damage to the pulmonary, cardiovascular, and renal systems, the most commonly affected organ systems in severe COVID-19.

Lymphocytes play an important role in the maintenance of immune system function. After virus infection, alteration in total lymphocyte numbers varies with different viral pathogenic mechanisms. Several mechanisms were shown before for virus induced lymphopenia including immune injuries from inflammatory mediators, virus attachment, exudation of circulating lymphocytes into inflammatory lung tissues. Recent studies indicated a clear association of decrease in peripheral lymphocytes with the clinical characteristics of COVID-19 patients. This indicates an impairment of the immune system during the course of SARS-CoV-2 infection. These alterations were also found in patients with pneumonia caused by MERS- CoV and SARS-CoV.

As per the reviewer’s suggestion, the necessary details are now included in lines 258-269, and 278-287 of the revised manuscript.

5. The authors do not mention anything about the ORF1ab, ORF3a, Spike, nucleocapsid or about ACE2 in the methods section and they also do not discuss about their importance or relevance to SARS-CoV-2 in this manuscript. The authors indicate the whole genome sequencing was performed only in patients with international travel history, but not in others. Is there a reason as to why there is a bias in this, as they anyway compare their sequences to those available from worldwide to determine the points of transmission.

Ans: The mutations observed in genes other than Spike are discussed (lines 363-378) in manuscript as per the reviewer’s suggestion. The discussion for ORF1ab and N protein is incorporated while there was no mutation observed in ORF3a. As a part of this discussion, a new figure (Fig 2) is now added to the revised manuscript depicting the graphical representation of polyprotein synthesized by orf1ab. The earlier mention of the mutation 24130C>T in ORF3a under the heading “Genetic variation in the sequences” in “Results and Discussion” section was incorrectly written. This position doesn’t lie in ORF3a, but belongs to the S gene. The text in the manuscript is now been corrected (line 335). As we did not analyze the mutation in ACE2 gene among different patients, discussion about ACE2 is out of scope of this manuscript, however the binding affinities of human ACE2 protein with the Spike protein has been studied and discussed in the manuscript.

The samples for the genome sequencing were taken from the patients with the international travel history, as they were the first samples available at the time of the study being initiated. No specific reason is considered in collecting the samples from patients with the international travel history. The comparison with globally available sequences is performed to compare the distribution of the samples among worldwide based on similarity and not to determine the point of transmission.

6. In the conclusion, the authors mention the patients exhibit higher immunological response compared to previous published reports. It is not clear as to what they mean by higher immunological response.

Ans: As per the reviewer’s suggestion, the sentence is removed from the revised manuscript due to the generalised and vague nature of the statement.

7. In the conclusion, the authors mention the radiological findings confirms the severity of infection. This is not clear, as they do not interpret the radiological findings in figure 1 as to how it is related to SARS-CoV-2. In addition to that, the authors need to indicate the number of patients for whom the radiological diagnosis were performed and their criteria, if any.

Ans: Radiological results are now discussed in lines 250-256 of the revised manuscript. A limitation of the current study is being unable to retrieve all the data regarding radiological findings which hindered us to compare the findings extensively in both groups. The same has been mentioned in lines 505-507 of the revised manuscript.

Response to the minor comments of the reviewers:

1. The authors need to pay attention to the errors related to English grammar in the results section and address that.

Ans: As per the reviewer’s suggestion, the manuscript is corrected with respect to English grammar to the best of our abilities.

2. The authors should also provide references in the methods section, wherever necessary, and this includes their description on sample collection by WHO guidelines and using the manufacturer/others protocol.

Ans: As per the reviewer’s suggestion, reference numbers 13, 14, 15 are now included in methods section on sample collection.

3. In the results section, the opening paragraph is not required, since the exact same information has been provided under the clinical and biochemical profile.

Ans: As per the reviewer’s suggestion, the opening paragraph of the results is now removed in the revised manuscript to avoid repetition.

4. The authors need to pay attention to the abbreviation when a particular word is written for the first time in the text or table.

Ans: Noted, and done.

5. It would be better if the authors indicate which statistical tests were used for comparing the difference between R and S groups in table 1 along with the results.

Ans: The statistical tests used in the current study for comparing the clinical findings is explained in the methods section in lines 189-198.

6. Which disease does reference 27 indicate?

Ans: Reference 27 is now reference 28 in the revised manuscript, and it refers to COVID-19.

7. Ratios are usually indicated as 1:2 and not as a number with +, clarity should be provided on the neutrophil and lymphocyte ratio.

Ans: Kindly note that there is no reference to ratios in the revised manuscript.

8. There is no reference for indicating SGOT and SGPT levels are associated with heart and liver infection.

Ans: As per the reviewer’s suggestion, reference 43 is now included for the same, in line 295 of the revised manuscript.

9. There is no reference for the health bulletin provided by Telangana government.

Ans: As per the reviewer’s suggestion, references 45, 46 are now included for the same, in line 307 of the revised manuscript.

10. In Figure 2, is the Clade – I/A3a or I/A3i, they are different in the text and figure.

Ans: In the text (under the heading “Phylogenetic analyses” in “Results and Discussion”) it was mistakenly written as I/A3a, which is now corrected to I/A3i in line 408 of the revised manuscript.

11. Is there any scale to distinguish between the two different panels in figure 6 A-D?

Ans: There is no scale to distinguish between the two different panels in figure 6 A-D (now figure 7). Only the zoomed picture of an interaction is represented for better visibility and convenience without following a fixed scale.

Attachment

Submitted filename: Response to reviewer comments_final.doc

Decision Letter 1

Binod Kumar

15 Jan 2021

Clinical and Whole Genome Characterization of SARS-CoV-2 in India

PONE-D-20-25334R1

Dear Dr. Kondapi,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Binod Kumar, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: All have comments have been addressed.

Additional suggestion: It would be better if the abbreviations R and S are changed to Recovered and Succumbed in the text, as it will be easier for the readers (this is because R and S are not universal abbreviations).

This is not mandatory, this change be made before submitting the final version.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Godhev Kumar Manakkat Vijay

Acceptance letter

Binod Kumar

22 Jan 2021

PONE-D-20-25334R1

Clinical and whole genome characterization of SARS-CoV-2 in India

Dear Dr. Kondapi:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Binod Kumar

Academic Editor

PLOS ONE


Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES